Kerry Conlin
she/her/hers
About
Research
Publications
2025
Personalized risk assessment of frailty in long-term cancer survivors
Forman R, Westvold S, Long J, Fan J, Hyslop T, Conlin K, Jacobson S, Wang S, Leapman M, Cecchini M, Leeds I, Spees L, Presley C, Yasin F, Taylor M, Kwaramba T, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of frailty in long-term cancer survivors. Journal Of Geriatric Oncology 2025, 17: 102804. PMID: 41319472, DOI: 10.1016/j.jgo.2025.102804.Peer-Reviewed Original ResearchCardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer
Westvold S, Long J, Fan J, Kc M, Hyslop T, Conlin K, Jacobson S, Silber A, Wang S, Leapman M, Leeds I, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer. Journal Of The National Cancer Institute 2025, 118: 130-140. PMID: 41069232, DOI: 10.1093/jnci/djaf243.Peer-Reviewed Original ResearchThis study investigates cardiovascular risk in older long-term cancer survivors, showing non-cancer factors, rather than cancer-specific ones, predict late-onset cardiovascular disease.Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study
Feng S, Bibi S, Aley P, Cappuccini F, Clutterbuck E, Conlin K, Ebrahimi N, Eordogh A, Faust S, Felle S, Green J, Gill H, Mujadidi Y, Oladunjoye I, Owino N, Plested E, Robinson H, Stuart A, Voysey M, Pollard A, Lambe T. Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study. Journal Of Infection 2025, 90: 106423. PMID: 39826861, DOI: 10.1016/j.jinf.2025.106423.Peer-Reviewed Original Research
2024
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial
Conlin K, Jenkin D, de Whalley P, Weckx L, Folegatti P, Bibi S, Lambe T, Aley P, Pollard A, Voysey M, Clemens S, Group C. Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial. Vaccine 2024, 45: 126582. PMID: 39675209, DOI: 10.1016/j.vaccine.2024.126582.Peer-Reviewed Original ResearchPaediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology
Martin N, Defres S, Willis L, Beckley R, Hardwick H, Coxon A, Kadambari S, Yu L, Liu X, Galal U, Conlin K, Griffiths M, Kneen R, Nadel S, Heath P, Kelly D, Solomon T, Sadarangani M, Pollard A, groups O. Paediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology. Journal Of Infection 2024, 88: 106145. PMID: 38552719, DOI: 10.1016/j.jinf.2024.106145.Peer-Reviewed Original Research
2023
Accelerating clinical development of a live attenuated vaccine against Salmonella Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of Salmonella Paratyphi A infection in healthy adult volunteers
McCann N, Emary K, Singh N, Mclean F, Camara S, Jones E, Kim Y, Liu X, Greenland M, Conlin K, Hill J, Verheul M, Robinson H, Angus B, Ramasamy M, Levine M, Pollard A. Accelerating clinical development of a live attenuated vaccine against Salmonella Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of Salmonella Paratyphi A infection in healthy adult volunteers. BMJ Open 2023, 13: e068966. PMID: 37225278, PMCID: PMC10230971, DOI: 10.1136/bmjopen-2022-068966.Peer-Reviewed Original Research